Overview

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Status:
Active, not recruiting

Trial end date:
2021-06-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Gliknik Inc.

Treatments:

Cyclophosphamide
Poly ICLC
Sargramostim